Sonoma Biotherapeutics Valuation, Funding & Investors

Sonoma Biotherapeutics is valued at $732M as of August 2021.

Last Sonoma Biotherapeutics valuation

$732M

Series B · Aug 2021

Last Sonoma Biotherapeutics funding round

$30M

Strategic investment · Mar 2023

Cumulative funding Sonoma Biotherapeutics raised

$365M

across 4 funding rounds

Key investors in Sonoma Biotherapeutics

  • 8VC
  • ARCH Venture Partners
  • Lyell Immunopharma
  • Alexandria Venture Investments
  • Lilly Asia Ventures
  • Ally Bridge Group

Sonoma Biotherapeutics Overview

About Sonoma Biotherapeutics

Sonoma Biotherapeutics is a South San Francisco-headquartered biotech firm engineering regulatory T-cell therapies for autoimmune diseases like celiac and inflammatory bowel conditions. Its allogeneic platform uses CRISPR editing for antigen-specific Tregs, advancing candidates through preclinical stages with manufacturing in Emeryville facilities.


Founded

2020

HQ

United StatesSan Francisco, CA

Status

Privately held

Customer focus

B2B

Revenue model

Licensing

Valuation

$732M (Aug 2021)

Sonoma Biotherapeutics Valuation

Sonoma Biotherapeutics is currently valued at $732M, based on its Series B in August 2021.

The $265M round was led by Ally Bridge Group.

Sonoma Biotherapeutics' valuation has grown 6.3x from $117M at its Series A in September 2020 to $732M in August 2021, across 2 priced rounds.

Sonoma Biotherapeutics valuation by funding round

Sonoma Biotherapeutics valuation by funding round
DateStageValuation
Aug 2021Series B$732M
Sep 2020Series A$117M

Sonoma Biotherapeutics Funding History

Sonoma Biotherapeutics has raised a total of $365M across 4 funding rounds.

Sonoma Biotherapeutics' first fundraising round was a $40M Series A in February 2020. The most recent completed round was a $30M strategic investment round in March 2023.

Sonoma Biotherapeutics funding rounds

Sonoma Biotherapeutics funding rounds
DateStageInvestorsRaisedValuationDeal Summary
Mar 2023Strategic investmentRegeneron (lead)$30M-Sonoma Biotherapeutics is a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, founded by immunologists Jeff Bluestone and Qizhi Tang. The company operates in South San Francisco and Seattle, with prior funding including a $265 million Series B in 2021, one of the largest biotech rounds that year, bringing total funding over $330 million from investors like Arch Venture Partners and Eli Lilly's venture arm. Sonoma's lead asset, SBT-77-7101, targets rheumatoid arthritis and was slated for clinical trials in 2023, with potential for additional trials in undisclosed indications. In March 2023, Sonoma entered a collaboration and license agreement with Regeneron Pharmaceuticals for Treg cell therapies targeting inflammatory bowel disease (ulcerative colitis, Crohn’s disease) and two undisclosed indications, with an option for a fifth. Regeneron provided $75 million upfront, comprising $45 million cash and $30 million equity investment in Sonoma, plus a potential $45 million development milestone, which was achieved by September 2024. The deal integrates Regeneron’s VelociSuite technologies for antibody and TCR discovery with Sonoma’s Treg engineering and manufacturing expertise. The partnership is structured as a true co-development effort, with both parties equally funding R&D, sharing commercial expenses and profits 50/50. Regeneron has the option to lead late-stage development and global commercialization, while Sonoma retains U.S. co-promotion rights and full ownership of independent programs like SBT-77-7101. Sonoma also leased an 83,000-square-foot facility to automate cell therapy manufacturing, potentially supporting Regeneron collaboration candidates. CEO Bluestone emphasized the deal's role in providing long-term runway and durability as a standalone company in the Treg space.
Aug 2021Series BAlly Bridge Group (lead)$265M$732MSonoma Biotherapeutics is a cell therapy company developing regulatory T cell (Treg) therapies and effector T cell (Teff) conditioning to treat autoimmune and inflammatory diseases, co-founded by pioneers like Jeffrey Bluestone and Qizhi Tang from UCSF. Sonoma positions itself to restore immune balance, targeting conditions like type 1 diabetes, with a world-class team to translate technologies from research to clinic. The company raised $265 million in an oversubscribed Series B financing in August 2021, led by Ally Bridge Group, with participation from new investors including ArrowMark, Avidity Partners, Casdin Capital, Deep Track Capital, Fidelity, Frazier Healthcare Partners, GV, Janus Henderson, Mirae Asset, NS Investment, Osage University Partners, Piper Heartland, Vertex Ventures HC, and others, plus existing backers like 8VC, ARCH Venture Partners, Alexandria Venture Investments, JDRF T1D Fund, LifeForce Capital, Lilly Asia Ventures, and Octagon Capital. This brought total funding since 2019 to over $335 million. The financing supports advancing Sonoma's platform into clinical development for curative medicines in autoimmune diseases. The leadership team includes experienced figures in cell therapy, genetic engineering, manufacturing, and a board chaired by Rick Klausner with members from top investors.
Sep 2020Series AJDRF T1D Fund; Lyell Immunopharma; 8VC; Alexandria Venture Investments; Octagon Capital Advisors; Lilly Asia Ventures; Lifeforce Capital; ARCH Venture Partners$30M$117MSonoma Biotherapeutics is a regulatory T cell (Treg) therapy company founded in 2019, developing adoptive cell therapies to treat autoimmune and inflammatory diseases. The company's platform aims to restore immune system balance through complementary regulatory T cell therapy and effector T cell conditioning, leveraging next-generation genome editing and target-specific cell therapy approaches. In September 2020, the company closed an expansion of its Series A financing bringing the total Series A raise to $70 million with a post-money valuation of $116.83 million. The round was led by a syndicate including Lyell Immunopharma, ARCH Venture Partners, 8VC, LifeForce Capital, Lilly Asia Ventures Biosciences, Octagon Capital, Alexandria Venture Investments, the JDRF T1D Fund, and additional investors. Proceeds were directed toward advancing the company's Treg cell therapy platform and expanding its management team with key clinical and drug development executives. The company went on to raise $265 million in a Series B financing in August 2021, demonstrating strong investor confidence in its cell therapy platform for treating severe autoimmune and inflammatory diseases.
Feb 2020Series ALyell Immunopharma; 8VC; Milky Way Ventures; ARCH Venture Partners$40M-Sonoma Biotherapeutics, a biotechnology company developing regulatory T cell (Treg) therapies for autoimmune and degenerative diseases, launched on February 6, 2020, with $40 million in Series A financing. The investor syndicate included Lyell Immunopharma, ARCH Venture Partners, Milky Way Ventures, and 8VC. The company, founded by pioneers in Treg biology and cell therapy including Jeffrey Bluestone (CEO), Fred Ramsdell (CSO), brings together expertise in next-generation genome editing, cell therapy, and manufacturing to create disease-modifying treatments. The Series A round supported advancing Sonoma's Treg cell therapy platform beyond oncology into autoimmunity and neuroinflammation. Sonoma's senior management included Peter DiLaura as Chief Business & Strategy Officer and Joshua Beilke as VP of Translational Development, with a board featuring experts like Rick Klausner. The financing enabled building proprietary methodologies for discovery and development of curative therapies across a spectrum of indications. This initial $40 million round was later expanded. On September 30, 2020, Sonoma raised an additional $30 million in Series A-II, bringing the total Series A to $70 million, with participation from Lyell Immunopharma, ARCH Venture Partners, 8VC, LifeForce Capital, Lilly Asia Ventures Biosciences, Octagon Capital, Alexandria Venture Investments, and the JDRF T1D Fund. New executives were appointed, including Leonard Dragone as CMO, Sejal Hall as VP of Portfolio Management, and Susan Lacy as VP of Discovery. Subsequent financings included an oversubscribed $265 million Series B on August 4, 2021, led by Ally Bridge Group, with existing investors like 8VC and ARCH Venture Partners, bringing total funding since 2019 inception to over $335 million. Later rounds included a $30 million corporate minority investment from Regeneron in March 2023 and a $45 million round in 2024, with cumulative funding reaching approximately $365 million across multiple rounds.

Who has invested in Sonoma Biotherapeutics?

11 investors have backed Sonoma Biotherapeutics across its funding rounds, including 8VC, ARCH Venture Partners, Lyell Immunopharma, Alexandria Venture Investments, Lilly Asia Ventures and Ally Bridge Group.

Lead investors include Regeneron and Ally Bridge Group.


Sonoma Biotherapeutics Investors

Investors in Sonoma Biotherapeutics by funding rounds participated
InvestorHQRoundsRoleFirst check
Lyell ImmunopharmaUnited StatesUnited States2ParticipantFeb 2020
8VCUnited StatesSan Francisco, CA2ParticipantFeb 2020
ARCH Venture PartnersUnited StatesChicago, IL2ParticipantFeb 2020
JDRF T1D FundUnited StatesBoston, MA1ParticipantSep 2020
Alexandria Venture InvestmentsUnited StatesLos Angeles, CA1ParticipantSep 2020
RegeneronUnited StatesUnited States1LeadMar 2023
Octagon Capital AdvisorsUnited StatesNew York City, NY1ParticipantSep 2020
Lilly Asia VenturesChinaShanghai1ParticipantSep 2020
Milky Way VenturesItalyMilan1ParticipantFeb 2020

This data is available for Pro users. Sign up to see all 11 Sonoma Biotherapeutics investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Sonoma Biotherapeutics Competitors

Sonoma Biotherapeutics competitors include listed companies like Aarti Pharmalabs and MapLight Therapeutics, and private ones like Terray Therapeutics, Alpha Biopharma, Letu and Belief BioMed.

Public and private companies comparable to Sonoma Biotherapeutics
CompanyHQStatusRevenueEBITDAValuation
Aarti PharmalabsIndiaIndiaPublicly listed$186M$40M$774M
Terray TherapeuticsUnited StatesLos Angeles, CAPrivate--$600M
Alpha BiopharmaChinaGuangzhouPrivate--$595M
LetuChinaShenzhenPrivate--$1.1B
Belief BioMedChinaShanghaiPrivate--$1.3B
MapLight TherapeuticsUnited StatesUnited StatesPublicly listed-($166M)$733M

Sonoma Biotherapeutics Public Comps

Sonoma Biotherapeutics is still privately-owned, but its public comps include MapLight Therapeutics, Oxford BioMedica, Collegium Pharmaceutical, Center Laboratories, Sanofi India, Nxera Pharma, Knight Therapeutics, Tempo Scan Pacific, XOMA Royalty and Supriya Lifescience.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
MapLight Therapeutics-($166M)--(2.6x)(2.1x)
Oxford BioMedica$227M($4M)3.5x3.1x(214.9x)78.3x
Collegium Pharmaceutical$781M$390M2.2x2.1x4.4x3.8x
Center Laboratories$48M($9M)15.4x-(82.6x)-
Sanofi India$190M$49M3.7x3.5x14.4x12.5x
Nxera Pharma$190M($26M)5.1x4.0x(37.2x)24.3x
Knight Therapeutics$323M$39M2.0x1.8x17.0x11.3x
Tempo Scan Pacific$790M$111M0.6x-4.5x-

This data is available for Pro users. Sign up to see all Sonoma Biotherapeutics competitors and their valuation data.

Start Free Trial

Common questions about Sonoma Biotherapeutics

When was Sonoma Biotherapeutics founded?Sonoma Biotherapeutics was founded in 2020.
Where is Sonoma Biotherapeutics headquartered?Sonoma Biotherapeutics is headquartered in San Francisco, CA, United States.
Is Sonoma Biotherapeutics publicly listed?No, Sonoma Biotherapeutics is a private, VC-backed company.
What is Sonoma Biotherapeutics' valuation?Sonoma Biotherapeutics was last valued at $732M in its Series B in August 2021.
How much funding has Sonoma Biotherapeutics raised?Sonoma Biotherapeutics has raised $365M across 4 funding rounds.
What was Sonoma Biotherapeutics' last funding round?Sonoma Biotherapeutics' last funding round was a $30M strategic investment round in March 2023, led by Regeneron.
Who are Sonoma Biotherapeutics' investors?Sonoma Biotherapeutics' investors include Lyell Immunopharma, 8VC, ARCH Venture Partners, JDRF T1D Fund, Alexandria Venture Investments, Regeneron, Octagon Capital Advisors, Lilly Asia Ventures, Milky Way Ventures, Lifeforce Capital and 1 other.
Which companies are comparable to Sonoma Biotherapeutics?Companies comparable to Sonoma Biotherapeutics include Aarti Pharmalabs, Terray Therapeutics, Alpha Biopharma, Letu, Belief BioMed and MapLight Therapeutics.

See companies similar to Sonoma Biotherapeutics

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial